Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.
Oncotelic Therapeutics has announced that its Chief Executive Officer, Dr. [CEO name], will be a featured speaker at the upcoming Ibero-American Chatbot and Conversational AI Summit. The online conference, set for [dates], will bring together a global audience and AI industry innovators to explore the vast field of conversational AI on a global scale.
Dr. [CEO name] will be discussing Oncotelic’s proprietary chatbots, which are part of the Orion AI Technology suite developed by the company. These advanced chatbots solve traditional AI communication challenges such as hallucination, dilution, depth, and convergence issues. With regular updates and a vast knowledge base supported by learning algorithms, the chatbots ensure consistent interactions regardless of data volume. Furthermore, Oncotelic’s AI suite has multilingual capabilities, making it accessible to non-English speakers and facilitating their participation in activities like clinical research by translating complex scientific literature.
Interested participants can register for the summit at [registration link]. For users who wish to gain early access to the beta technology, they can visit and register at [beta access link].
Dr. [CEO name] emphasized the importance of effective communication across experience levels and technical disciplines in the pursuit of breakthroughs in drug discovery. He highlighted that Oncotelic’s advanced chatbot technology surpasses the limitations of raw Large Language Models like ChatGPT. The technology distills and leverages complex documents to provide actionable insights throughout the organization. Additionally, Oncotelic’s chatbot technology democratizes scientific engagement on a global scale by breaking language barriers and increasing accessibility.
The Ibero-American Chatbot and Conversational AI Summit serves as a vital platform for stakeholders in the Spanish and Portuguese markets to engage with conversational AI innovations and explore their applications in the biotechnology industry. By enhancing research methodologies and streamlining processes, these innovations contribute to cost-effective solutions and increased profitability. Dr. [CEO name]’s presentation will underscore the potential of conversational AI to transform the biotech industry while addressing language barriers.
The summit, scheduled for [dates], is designed to encourage in-depth discussions on strategic utilization of conversational AI to streamline business operations, enhance research capabilities, and improve profitability. It offers complimentary registration, enabling professionals from various regions to network and gain valuable insights. More details about the summit can be found on the official event website.
About Oncotelic:
Oncotelic Therapeutics, formerly known as [previous name], was established in [year] and has since focused on leveraging its deep expertise in oncology drug development. The company aims to improve treatment outcomes and survival for cancer patients, particularly those with rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG), melanoma, and Acute Myeloid Leukemia through its joint venture. In addition, Oncotelic acquired AL-101 for the treatment of Parkinson’s Disease, erectile dysfunction, female sexual disorder, and hypoactive sexual desire disorder. The company’s commitment to innovation led to the development of an AI-driven biotechnology company and the acquisition of AL-101. For more information, please refer to the company’s filings with the [relevant regulatory agency].
Oncotelic’s Cautionary Note on Forward-Looking Statements:
This press release contains forward-looking statements regarding the company’s strategy, future operations, financial position, prospects, and plans. These statements are subject to risks and uncertainties that may cause actual results to differ materially from the expectations and assumptions mentioned. The company does not assume any obligation to update these forward-looking statements. For a comprehensive understanding of the risks involved, please refer to the company’s filings with the [relevant regulatory agency].
As an ethical and quality-driven news agency, we prioritize delivering factual information and maintaining legal and ethical standards. Our goal is to provide engaging and informative content for our global audience, considering their interests and needs.
